Indian drugmaker launches Lucentis biosimilar; Celyad raises $100M in IPO;

@FierceMedDev: UPDATED with comments from Cynvenio CEO: Cynvenio Biosystems ropes in $25M for liquid biopsy technology. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: Biotie nets $56M+ in IPO, fellow Parkinson's player Cynapsus up next, followed by Intec Pharma. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Chinese med tech gets the WHO's OK for circumcision device. Article | Follow @EmilyWFierce

> India's Intas Pharmaceuticals launched the world's first biosimilar of Roche's ($RHHBY) blockbuster Lucentis. News

> Belgian biotech Celyad ($CYAD) raised $100 million in an IPO to support its pipeline of gene therapies. More

Biotech News

@FierceBiotech: ICYMI yesterday: Merck KGaA hustling a promising anti-malaria drug into human studies. Report | Follow @FierceBiotech

@JohnCFierce: $TKMR down 15% on the ebola miss. | Follow @JohnCFierce

@DamianFierce: FierceBiotech Radio releases its first double album. This is our All Eyez on Me. More | Follow @DamianFierce

> Lilly and Teva tout new migraine data amid a crowded race. Story

> Antibiotics biotech Nabriva shoots for a $92M IPO. News

> Tekmira's Ebola drug comes up short in Phase II. Article

Pharma News

@FiercePharma: UPDATED: U.S. court nixes Teva's Copaxone patent--again. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI: Merck inks $5.9M settlement to wrap up AzaSite off-label investigation. Article | Follow @CarlyHFierce

> Amgen's Vectibix hits PhIII survival goal in previously treated mCRC patients. Item

> Teva turns up the heat on Mylan, taking its stake past critical threshold. Story

> Celgene hits speedbump for Otezla in U.K. with NICE rejection. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.